Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18335379 | 1.00 | GBA1 (0.32) | GBA1CYP3A4 | |
| SCHEMBL18335378 | 0.97 | GBA1 (0.35) | GBA1 | |
| SCHEMBL18335397 | 0.95 | CYP3A4 (0.30) | CYP3A4 | |
| SCHEMBL18335407 | 0.95 | GBA1 (0.37) | GBA1CYP3A4 | |
| SCHEMBL4374229 | 0.90 | SLC2A1 (0.33) | GBA1CYP3A4 | |
| SCHEMBL13528521 | 0.86 | SLC2A1 (0.33) | CYP3A4 | |
| SCHEMBL17131873 | 0.86 | SLC2A1 (0.33) | CYP3A4 | |
| SCHEMBL827322 | 0.86 | ALDH1A1 (0.35) | CYP3A4 | |
| SCHEMBL9439413 | 0.78 | BCHE (0.52) | CYP3A4 | |
| SCHEMBL9293835 | 0.78 | BCHE (0.52) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109689634-A | The manufacturing method of polynary glycidyl compound | 昭和电工株式会社 | 2019-04-26 | — | — | CN | disclosed |
| US-20040131551-A1 | Enhanced relaxivity monomeric and multimeric compounds | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-08 | — | — | US | disclosed |
| US-6693190-B1 | TETRAAZACYCLODODECANE MACROCYCLE DERIVATIVES INCLUDING METAL COMPLEXES; MAGNETIC RESONANCE IMAGING AGENTS | BRACCO INTERNATIONAL B.V. (NL) | 2004-02-17 | — | — | US | disclosed |
| EP-0708761-B1 | ENHANCED RELAXIVITY MONOMERIC AND MULTIMERIC COMPOUNDS | BRACCO INT BV (NL) | 2002-08-14 | — | — | EP | disclosed |
| WO-1995031444-A1 | ENHANCED RELAXIVITY MONOMERIC AND MULTIMERIC COMPOUNDS | BRACCO INTERNATIONAL B.V. (NL) | 1995-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040131551-A1 | Enhanced relaxivity monomeric and multimeric compounds | H1-2, H1-0, H1-3 | GBA1 2439/4885CYP3A4 3246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.